<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461446</url>
  </required_header>
  <id_info>
    <org_study_id>P00013150</org_study_id>
    <secondary_id>1U54NS092090-01</secondary_id>
    <nct_id>NCT02461446</nct_id>
  </id_info>
  <brief_title>Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations</brief_title>
  <official_title>Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine cross-sectional and longitudinal medical,
      behavioral, and cognitive differences between PTEN ASD and other groups, as well as to
      identify cognitive, neural systems, and molecular biomarkers specific to PTEN ASD. In
      addition, this study will be creating and maintaining a biorepository and linked phenotypic
      database for PTEN ASD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autism spectrum disorders (ASD) are a set of neurodevelopmental disorders characterized by
      social communication/interaction impairments and restricted/repetitive behaviors. ASD
      associated with germline heterozygous PTEN mutations (PTEN ASD) is a genetically defined
      sub-group that, may be one of the more prevalent genetic disorders contributing to ASD
      (0.5-2%). The purpose of this research study is to carefully track the phenotypic and
      molecular characteristics of PTEN ASD and identify biomarkers for intervention studies.

      Individuals with PTEN ASD, with macrocephalic ASD without a PTEN mutation (macro-ASD),
      healthy controls, and individuals with PTEN mutations without ASD (PTEN no-ASD) will be asked
      to participate in this study if they are 18 months and older. Both males and females will be
      asked to participate. Additionally, to be eligible for study participation, individuals'
      primary communicative language must be English.

      The study involves 3 on site visits over the course of two years. Study visits will vary in
      length from about 4 hours to 6 hours. Study visits involve a physical exam, medical history
      questions, neuropsychological assessments, and a blood draw done for laboratory studies. A
      subset of participants between the ages of 2 and 11 years old will take part in the EEG
      portion of the study. Individuals who have a clinically indicated MRI will have an option to
      provide routine clinical scans for analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in verbal abilities at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Verbal and non-verbal ability will be evaluated using Stanford Binet -5 or Mullen Scales of Early Learning (MSEL) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in communication ability at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Communication ability will be evaluated using composite score of the Peabody Picture Vocabulary Test (PPVT-4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in communication ability at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Communication ability will be evaluated using composite score of the Expressive Vocabulary Test (EVT-2) at 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in verbal abilities at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Verbal and non-verbal ability will be evaluated using Stanford Binet 5 or Mullen Scales of Early Learning (MSEL) at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in visual perception at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Visual perception will be measured using the Beery Developmental Test of Visuomotor Integration (VMI) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in working memory at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Working memory will be evaluated using the Stanford Binet 5 at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in processing speed at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Processing Speed will be measured using the Processing Speed Index from the Weschler Intelligence Scales at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in working memory at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Working memory will be evaluated using the Stanford Binet 5 at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in processing speed at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Processing Speed will be measured using the Processing Speed Index from the Weschler Intelligence Scales at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in visual perception at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Visual perception will be measured using the Beery Developmental Test of Visuomotor Integration (VMI) at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in communication ability at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Communication ability will be evaluated using composite score of the Peabody Picture Vocabulary Test (PPVT-4) at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in communication ability at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Communication ability will be evaluated using composite score of the Expressive Vocabulary Test (EVT-2) at 24 months.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>PTEN</condition>
  <condition>ASD</condition>
  <condition>Autism</condition>
  <condition>Macrocephaly</condition>
  <condition>PTEN Hamartoma Tumor Syndrome</condition>
  <arm_group>
    <arm_group_label>PTEN ASD</arm_group_label>
    <description>PTEN participants with Autism Spectrum Disorder group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTEN no ASD</arm_group_label>
    <description>PTEN participants without Autism Spectrum Disorder group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTEN Macrocephaly</arm_group_label>
    <description>PTEN participants with Macrocephaly group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy control group</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood draw for future correlative studies in the PTEN Biorepository of the Developmental
      Synaptopathies Consortium.

      170 subjects; 100 existing subjects, 70 newly enrolled participants; 50 controls
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        170 patients will be enrolled for this study, over the age of 18 month old.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Individuals above the age of 18 months old at the time of consent who have
             documentation of a clinical diagnosis of autism spectrum disorder and/or a verified
             PTEN mutation from a medical or mental health professional for inclusion in the PTEN
             ASD, PTEN no-ASD or ASD macrocephaly groups.

          -  Macrocephaly (head circumference greater than or equal to 98th percentile) for
             inclusion in the ASD macrocephaly group.

          -  For youths, consent from parents or legal guardian. For adults, consent from self or
             legal guardian.

          -  Youths who are able (some young or severely impaired participants may not be able to
             provide assent) will be asked to provide assent as per IRB guidelines.

          -  Families with multiple children who meet the above inclusion criteria will be
             permitted to have as many children participate as they wish. A separate consent form
             will be filled out for each child enrolled in the study.

          -  Primary communicative language must be English

        Exclusion Criteria

          -  Unwilling or unable to comply with study procedures and assessments

          -  Clinically significant medical disease that would prohibit participation in the study
             procedures.

          -  For subjects ELIGIBLE FOR OPTIONAL imaging biomarker assessment: contraindications to
             3T MRI scanning, such as metal implants/non-compatible medical devices or medical
             conditions, including vagus nerve stimulator.

          -  For subjects ELIGIBLE FOR EEG/ERP biomarker assessment: contraindications to EEG/ERP,
             such as uncooperative or destructive behaviors preventing lead placement or capture by
             ERP/VEP equipment. Under age 2 or over 11 at the time of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charis Eng, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajna Filip-Dhima, MS</last_name>
    <phone>617-919-7068</phone>
    <email>Rajna.Filip-Dhima@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irma Gutierrez</last_name>
      <phone>310-794-5065</phone>
      <email>IrmaGutierrez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Julian Martinez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Libove</last_name>
      <phone>650-736-1235</phone>
      <email>rlibove@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jaelyn Edwards</last_name>
      <email>jedwards@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Hardan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Mason</last_name>
      <phone>617-919-3499</phone>
      <email>Amy.Mason@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Mustafa Sahin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Griffith</last_name>
      <phone>513-636-9669</phone>
      <email>Molly.Griffith@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Darcy Krueger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Green</last_name>
      <phone>216-448-6392</phone>
      <email>greenh@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Beth Crouser</last_name>
      <phone>216-636-5535</phone>
      <email>crouseb@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Charis Eng, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Mustafa Sahin</investigator_full_name>
    <investigator_title>Assistant in NeurologyAssociate Professor of Neurology, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>germline heterozygous PTEN mutations</keyword>
  <keyword>MRI</keyword>
  <keyword>10q23.3</keyword>
  <keyword>ASD</keyword>
  <keyword>Autism</keyword>
  <keyword>Macrocephaly</keyword>
  <keyword>PTEN Hamartoma Tumor Syndrome</keyword>
  <keyword>PTEN</keyword>
  <keyword>EEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hamartoma</mesh_term>
    <mesh_term>Hamartoma Syndrome, Multiple</mesh_term>
    <mesh_term>Megalencephaly</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

